Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Dendreon nets $410mm through latest follow-on offering

Executive Summary

Cancer drug company Dendreon netted $410mm through the public sale of 17.25mm common shares (including the overallotment) at $24.75 each. Proceeds will be used to prepare for the launch of the company's late-stage prostate cancer candidate Provenge, and to fund the construction of new manufacturing facilities and the build-out of existing ones.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies